Guselkumab
Brand name: Tremfya
Rank #164 of 500 drugs by total cost
$97.1M
Total Cost
7,102
Total Claims
$97.1M
Total Cost
393
Prescribers
$14K
Cost per Claim
128
Beneficiaries
12,783
30-Day Fills
$247K
Avg Cost/Provider
18
Avg Claims/Provider
About Guselkumab
Guselkumab (sold as Tremfya) was prescribed 7,102 times by 393 Medicare Part D providers in 2023, costing the program $97.1M. At $14K per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 161 | Brimonidine Tartrate (Alphagan P) | $98.8M | 988,570 |
| 162 | Dexlansoprazole (Dexlansoprazole Dr) | $98.7M | 275,116 |
| 163 | Interferon Beta-1a (Avonex) | $98.3M | 11,314 |
| 164 | Guselkumab (Tremfya) | $97.1M | 7,102 |
| 165 | Levetiracetam (Levetiracetam) | $96.1M | 1,723,736 |
| 166 | Oxycodone Myristate (Xtampza Er) | $96.1M | 141,266 |
| 167 | Sevelamer Carbonate (Sevelamer Carbonate) | $95.6M | 277,192 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology